



Anika Therapeutics Comments on Patent Litigation

BEDFORD, Mass., Jul 12, 2010 (BUSINESS WIRE) --

Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid ("HA") technology, announced today that they had been served with a complaint alleging patent infringement with respect to the MONOVISC product by Genzyme Corporation. This complaint was filed in the United States District Court for the District of Massachusetts on July 7, 2010. The company intends to vigorously defend the lawsuit and the MONOVISC product franchise.

About Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., **Anika Therapeutics, Inc.** develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on **hyaluronic acid (HA)**, a naturally occurring, biocompatible polymer found throughout the body. Anika's products range from orthopedic/joint health solutions led by **ORTHOVISC®**, a treatment for osteoarthritis of the knee; to surgical aids in the **ophthalmic** and **anti-adhesion** fields. The company also offers **aesthetic dermal fillers** for the correction of facial wrinkles. Anika's Italian subsidiary, Fidia Advanced Biopolymers, S.r.l (FAB), provides complementary HA products in orthopedic/joint health and anti-adhesion, as well as therapeutics in new areas such as advanced wound treatment and ear, nose and throat care. FAB's regenerative tissue technology advances Anika's vision to offer therapeutic products that go beyond pain relief to protect and restore damaged tissue.

The statements made in this press release which are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, statements that may be identified by words such as "expectations," "remains," "focus," "expected," "prospective," "expanding," "building," "continue," "progress," "plan," "efforts," "hope," "believe," "objectives," "opportunities," "will," "seek," "expect" and other expressions which are predictions of or indicate future events and trends do not constitute historical matters and identify forward-looking statements. These statements also include those relating to the expectation that the patent litigation will be vigorously defended. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks, uncertainties and other factors. The Company's actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors including: the litigation's potential adverse impact on the Company, its business or financial expectations, including with respect to the MONOVISC product, the Company's ability to launch MONOVISC in the U.S., if at all, the actions in the litigation of the plaintiff and the court, or the market impact of the litigation. There is also risk that (i) the Company's efforts to enter into long-term marketing and distribution arrangements, including with new international distributors for ORTHOVISC and MONOVISC, will not be successful, (ii) new distribution arrangements will not result in meaningful sales of the Company's products, (iii) the Company's distributors will be unable to achieve performance and sales threshold milestones in its distribution agreements, (iv) competitive products will adversely impact the Company's product sales, (v) the estimated size(s) of the markets which the Company has targeted its products will fail to be achieved, (vi) lack of adequate coverage and reimbursement provided by governments and other third party payers for our products and services could have a material adverse effect on our results of operations, or (vii) increased sales of the Company's products, including HYVISC, ORTHOVISC, or its ophthalmic products, will not continue or sales will decrease or not reach historical sales levels, or even if such increases occur that such increases will improve gross margins, any of which may have a material adverse effect on the Company's business and operations. Certain other factors that might cause the Company's actual results to differ materially from those in the forward-looking statements include those set forth under the headings "Business," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, as well as those described in the Company's other press releases and SEC filings.

SOURCE: Anika Therapeutics, Inc.

Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D., CEO, 781-457-9000
or
Kevin W. Quinlan, CFO, 781-457-9000

<https://ir.anika.com/news-releases?item=246>